Abstract
The Hippo pathway negatively regulates the cell number in epithelial tissue. Upon its inactivation, an excess of cells is produced. These additional cells are generated from an increased rate of cell division, followed by inappropriate proliferation of cells that have failed to exit the cell cycle. We analyzed the consequence of inactivation of the entire E2F family of transcription factors in these two settings. In Drosophila, there is a single activator, dE2F1, and a single repressor, dE2F2, which act antagonistically to each other during development. While the loss of the activator dE2F1 results in a severe impairment in cell proliferation, this defect is rescued by the simultaneous loss of the repressor dE2F2, as cell proliferation occurs relatively normally in the absence of both dE2F proteins. We found that the combined inactivation of dE2F1 and dE2F2 had no significant effect on the increased rate of cell division of Hippo pathway mutant cells. In striking contrast, inappropriate proliferation of cells that failed to exit the cell cycle was efficiently blocked. Furthermore, our data suggest that such inappropriate proliferation was primarily dependent on the activator, de2f1, as loss of de2f2 was inconsequential. Consistently, Hippo pathway mutant cells had elevated E2F activity and induced dE2F1 expression at a point when wild-type cells normally exit the cell cycle. Thus, we uncovered a critical requirement for the dE2F family during inappropriate proliferation of Hippo pathway mutant cells.
Author Summary
The E2F transcription factor family is considered to be the best-characterized downstream target of the retinoblastoma protein (pRB). The pRB pathway is functionally inactivated in most tumor cells, and it is thought that unrestrained activity of E2F drives inappropriate proliferation in tumors. We utilized the relative simplicity of the Drosophila model to determine the role of the dE2F family in proliferation of cells following inactivation of the recently identified Hippo tumor suppressor pathway. We found that Hippo pathway mutant cells require the dE2F family to delay the cell cycle exit and to proliferate inappropriately when wild-type cells enter quiescence. This is significant since the loss of the entire dE2F family exerts almost no effect on the ability of Hippo pathway mutations to accelerate proliferation of actively dividing cells. Thus, the importance of the dE2F family in cells with an inactivated tumor suppressor pathway varies in different contexts. This discovery may have implications in designing anti-cancer therapies that inhibit E2F activity.
Introduction
The Retinoblastoma tumor suppressor protein (pRB) and the related proteins p107 and p130 negatively regulate cell proliferation. In a textbook model, the role of pRB family members in cell cycle regulation is explained by their ability to attenuate the activity of E2F transcription factors. E2F is best known for its ability to control the G1/S transition and is rate limiting for S phase entry (for review see: [1]–[4]). The E2F transcriptional program provides cell cycle dependent expression of a large panel of genes encoding replication proteins, cell cycle regulators and others. In early G1 phase, members of the pRB family are complexed with members of the E2F family and repress expression of E2F regulated genes through recruitment of corepressor complexes to target promoters. In late G1 phase, cyclin dependent kinases phosphorylate pRB family members, thus releasing free E2F proteins to allow induction of E2F-dependent transcription. Since functional inactivation of the pRB pathway occurs in most tumor cells it is thought that unrestrained E2F activity drives inappropriate proliferation in tumors [5]. Such an idea is further supported by findings that mutations in E2f genes reduce proliferation in Rb deficient mouse embryos [6]–[8].
In mammalian cells, E2F activity is a combined output of eight family members, which, in turn, are loosely grouped into a class of repressors (E2F-3b through E2F-8) and a class of activators (E2F-1 through E2F3a). E2F-1 through E2F-6 require a heterodimeric partner of the DP family of proteins to bind to DNA, while E2F-7 and E2F-8 bind to DNA in a DP-independent manner. As a way to dissect the contribution of E2F to cell proliferation, dominant negative forms of DP and E2F, dn-DP and dn-E2F respectively, were used. Expression of dn-E2F, which binds to DNA, but fails to repress or activate, leads to immortalization in mouse fibroblasts and renders cells resistant to senescence induced by p19ARF, p53 or by RASV12 [9]. However, cells expressing dn-E2F were impaired in the ability to proliferate following serum stimulation. This suggests that E2F activity is not needed during cell proliferation but is required in a specific context, such as cell cycle re-entry from quiescence. In contrast, a reduction of DP function, either by siRNA or by using a dn-DP form, resulted in cell cycle arrest and a senescence-like phenotype, indicating that E2F is in fact needed for cell proliferation [10],[11]. One potential explanation for these discrepancies is that reducing DP does not inactivate the total pool of E2Fs, since E2F-7 and E2F-8 repressors bind to DNA in a DP-independent manner, and therefore the two remaining E2Fs may induce the cell cycle arrest. An alternative explanation is that dn-E2F does not completely inhibit E2F activity [11] and the remaining E2F activity is sufficient to sustain cell proliferation.
The biological role of E2F in the context of animal development is being extensively studied by using gene targeting approaches in mice. However, interpretation of the phenotypes of individual E2F knockouts is often complicated by the redundancy and compensation among the family members. The impact of genetic ablation of E2f genes on cell proliferation is more profound in compound knockouts. Mouse embryonic fibroblasts (MEFs) lacking a whole class of activator E2Fs, E2f-1, E2f-2 and E2f-3, fail to proliferate due to a high level of p21 [12], E2f-4; E2f-5 double knockouts are defective in a p16 mediated cell cycle arrest [13], while E2f-7; E2f-8 knockouts have a high level of apoptosis due to deregulation of E2f-1 expression [14]. Nevertheless, the large number of E2F genes makes it currently unfeasible to genetically ablate all E2F activity in mammals to determine the consequences of the loss of E2F function on cell proliferation.
Genetically, Drosophila provides a relatively simpler system to study the role of E2F, since the corresponding families are smaller. The Drosophila E2F family consists of a single activator, dE2F1, and a lone repressor, dE2F2. Both dE2Fs dimerize with the single dDP protein in order to bind to DNA. Unlike mammalian cells, the Drosophila genome lacks orthologs of E2F-7 or E2F-8 that bind to DNA in a dDP independent manner. It is important to note that the loss of dDP has been shown to functionally inactivate both dE2F1 and dE2F2 [15]. A de2f1 mutation severely reduces cell proliferation, leads to the loss of expression of E2F target genes, and almost complete cessation of DNA synthesis [16],[17]. Strikingly, these defects are largely suppressed by a concomitant mutation in de2f2. de2f1 de2f2 double mutant animals can survive until late pupal stages and show normal patterns of cell proliferation and differentiation even though E2F targets are no longer expressed in a cell cycle dependent manner and are likely to be present at suboptimal levels [18]. A similar phenotype has been observed in dDP mutant animals. Thus, the complete loss of E2F function in dDP or in de2f1 de2f2 mutants is permissive for cell proliferation and appears to have a relatively minor impact on animal development; however, whether the loss of E2F affects cell proliferation during oncogenic stimuli has not been studied. Given that most models emphasize the prominent role of E2F in proliferation of tumor cells, this is an important question to be addressed.
Drosophila has proven to be an excellent model to investigate cancer-causing genes. This is illustrated, for example, by studies of the recently identified the Hippo tumor suppressor pathway. The cellular functions of the Hippo pathway are to restrict cell proliferation and promote apoptosis (for review see: [19]–[22]). The core components of the pathway are the protein kinases Warts (Wts), Hippo (Hpo) and Mob as tumor suppressor (Mats). Salvador (Sav) serves a scaffold for Wts and Hpo. Assembly of an active complex of the four negative regulators Wts/Hpo/Mats/Sav is accompanied by mutual phosphorylation and leads to activation of the Wts kinase. Once active, Wts phosphorylates and inactivates the transcriptional co-activator Yorkie (Yki) by excluding Yki from nucleus. Yki is thus far the most downstream component of the pathway. In the absence of Wts-dependent phosphorylation, Yki enters the nucleus where it requires transcription factors to be recruited to the promoter of the Hippo pathway target genes. Thus far, only the lone TEAD/TEF protein family member in Drosophila, Scalloped, has been shown to interact with Yki [23],[24] while the Yki mammalian homolog YAP binds to a variety of transcriptional factors and modulates their activity. Among Hippo pathway targets are genes that promote cell proliferation and genes that inhibit apoptosis such as cyclin E, microRNA bantam, and diap1. Inactivation of any negative regulator of Hippo pathway signaling, or overexpression of the positive regulator Yki, stimulates additional cell divisions by increasing the proliferation rate of actively dividing cells, delaying the cell cycle exit, and simultaneously protecting cells from apoptosis. Failure to exit the cell cycle on time gives rise to inappropriate proliferation of Hippo pathway mutant cells. Since patterns of cell proliferation are normal in dDP mutants and in de2f1 de2f2 double mutants, these combinations provide us with an opportunity to determine when and where proliferation driven by the potent oncogene Yki is dependent on dE2F family members. In this work, we show that the loss of E2F function produces a distinctly different result in actively dividing cells and in cells that proliferate inappropriately due to the failure to exit the cell cycle. Inactivation of the entire dE2F family in actively dividing cells has only a subtle effect on the ability of Yki to increase the rate of cell division. In contrast, the loss of E2F function fully blocks inappropriate proliferation of these cells. Thus, our work uncovers the in vivo requirement for E2F function during oncogenic proliferation driven by Yki, specifically at the point when cells normally exit the cell cycle and enter quiescence.
Results
Yki-Driven Proliferation of Actively Dividing Cells in the Wing Imaginal Disc Does Not Require E2F Mediated Control
We initially used a dDP mutation to determine whether Yki requires dE2F mediated control to drive cell proliferation. dDP is an obligatory heterodimeric partner of both dE2F1 and dE2F2, and the loss of dDP has been shown to functionally inactivate both de2f1 and de2f2 [15]. Importantly, dDP single mutant or de2f1 de2f2 double mutant animals survive until late pupal stages and exhibit normal patterns of cell proliferation [17],[18]. Thus, the use of these mutant combinations allowed us to minimize indirect cell cycle effects produced when dE2F1 function alone is inactivated. The MARCM technique [25] was employed to generate clones of wild-type cells, wild-type cells overexpressing yki, dDP mutant cells, and dDP mutant cells that overexpress yki in the larval wing imaginal disc. All clones were marked with GFP, induced simultaneously, and allowed to grow for the same period of time (Figure 1). At this stage of development, the majority of cells in the wing disc are asynchronously dividing and therefore the rates of cell proliferation can be accurately measured. As expected, overexpression of yki accelerated the cell cycle progression of wild type cells (Figure 1A–B). The median population doubling time in yki overexpressing clones was 10.6 hr. This was faster than that of the wild type population, which was 13.8 hr. We found that a dDP mutation did not significantly affect the ability of yki to increase rates of cell division (Figure 1C–D). The median population doubling time in clones of dDP mutant cells overexpressing yki was 11.3 hr, indicating that these cells were still proliferating faster than wild type cells. Thus, this result suggests that E2F mediated control is not required for Yki induced proliferation in actively dividing cells.
The Loss of E2F–Dependent Control Blocks Yki-Driven Inappropriate Proliferation in the Cells Posterior to the SMW in the Eye Imaginal Disc
In the eye imaginal disc, Hippo pathway mutant cells delay the cell cycle exit and undergo inappropriate proliferation. To determine the effect of the loss of E2F mediated regulation in these settings, we examined the effect of yki overexpression in clones of wild type or dDP mutant cells during cell cycle exit. In a wild type eye disc, BrdU labeling reveals a narrow stripe of S phase cells posterior to the morphogenetic furrow (MF), referred to as the Second Mitotic Wave (SMW) (Figure 2A). Cells within the MF are arrested in G1 and therefore do not incorporate BrdU. Posterior to the SMW, cells exit the cell cycle and differentiate. In contrast, yki overexpressing cells (GFP positive) failed to undergo cell cycle exit and continued proliferating [26], as shown by the appearance of BrdU positive cells posterior to the SMW (Figure 2B). Strikingly, no ectopic BrdU incorporation was observed when yki was overexpressed in clones of dDP mutant cells, which are marked by the presence of GFP (Figure 2C). This indicates that although E2F function is unnecessary for Yki to increase rates of cell proliferation in actively dividing cells, Yki is dependent on the presence of dE2F/dDP activity to drive cells into inappropriate cell cycles posterior to the SMW.
To further confirm this conclusion, we examined cell proliferation when both de2f1 and de2f2 were genetically ablated while the Hippo pathway was inactivated by a wts mutation. Clones of de2f2 single, de2f1 wts double, and de2f2 de2f1 wts triple mutant cells were simultaneously generated in the same eye imaginal disc using the ey-FLP/FRT technique. The triple mutant tissue could be distinguished from the neighboring wild type tissue by the complete lack of GFP. Similar to yki overexpressing cells, wts mutant cells failed to exit the cell cycle and proliferated inappropriately posterior to the SMW [27],[28] (Figure 2D). Additionally, wts mutant cells continue cell divisions during early pupal development when wild type cells are quiescent (Figure 2G). The inappropriate proliferation during larval and pupal stages gives rise to a surplus of interommatidial cells. During pupal eye development, the excess of interommatidial cells is eliminated by a wave of apoptosis. However, since wts mutants are defective in normal apoptosis in the eye, these supernumerary cells remain and can be visualized in 48 hr old pupal retina as extra layers of cells between adjacent ommatidial clusters (Figure 2J). Consistent with the results of the overexpression of yki in dDP mutant cells (Figure 2C), clones of de2f2 de2f1 wts mutant cells posterior to the SMW were largely devoid of BrdU incorporation and mitoses, the latter were detected by the appearance of phosphorylated histone H3 (phosH3), (Figure 2E–F). No S phases were detected in the triple mutant combination at 12 hr after puparium formation either (Figure 2H), a time point when wts mutant cells continue inappropriate proliferation (Figure 2G). Furthermore, examination of pupal retinas revealed that clones of de2f1 de2f2 wts triple mutant cells (Figure 2K) or dDP mutant cells that overexpress yki (Figure 2M) no longer contain an abnormally large number of supernumerary interommatidial cells which are otherwise found in clones of wts mutant cells (Figure 2J) or in clones of cells that overexpress yki (Figure 2L). To measure the extent to which the loss of dE2F function reduced the number of interommatidial cells in wts mutant tissue, we counted the number of secondary, tertiary, and bristles cells per each ommatidial hexagon. Clones of wts mutant tissue in pupal retinas contained an average of 31.6±2.6 cells, which was significantly higher than 12.0±0.1 cells found in wild type tissue (Figure 2N). However, the regions that were triple mutant for de2f1 de2f2 wts had only 13.7±1.0 cells. Similarly, a dDP mutation significantly reduced the number of cells in clones that overexpress yki from 30.3±3.3 down to 15.0±1.0 (Figure 2N). These reductions are consistent with the observations that these cells fail to proliferate posterior to the SMW. We further emphasize that the inability of wts mutant cells, or yki overexpressing cells, to undergo inappropriate proliferation in the absence of E2F control is not merely a consequence of non-specific cell cycle defects due to inactivation of the dE2F family. Most cell proliferation occurs normally in de2f1 de2f2 double mutants [18] or dDP mutants [17] and, as shown here, a dDP mutation did not prevent yki from increasing rates of cell division in asynchronously dividing cells of the wing disc (Figure 1).
Next, we wished to determine whether both dE2F family members are equally important in wts mutant cells to undergo inappropriate proliferation. To address this question we compared the S phases posterior to the SMW in clones of de2f2 wts double mutant cells with that of wts single mutant cells in the same eye imaginal disc. Previous analysis revealed that patterns of cell proliferation are normal in clones of de2f2 mutant cells [29]. The de2f2 wts double mutant cells were marked by the lack of GFP, wts single mutant cells were distinguished by an intermediate GFP signal and by the increased spacing between ommatidial clusters, while the wild type cells had the highest intensity of GFP (Figure 3A). The loss of de2f2 had no effect on inappropriate S phases posterior to the SMW in wts mutant cells, as the phenotype of de2f2 wts mutant cells was indistinguishable from the phenotype of wts mutant cells (Figure 3B–D). Additionally, the spacing between adjacent ommatidial clusters (marked with Elav) is increased in clones of de2f2 wts double mutant cells when compared to that of wild type cells. Such increase reflects the appearance of additional interommatidial cells in the wts mutant tissue [27]. Taken together with the results described above, this indicates that de2f2 is not important for the phenotype of wts mutant cells and that de2f1 is required for inappropriate proliferation of wts mutant cells. Consistently, no ectopic S phases were detected in de2f1 wts double mutant clones (data not shown).
In addition to delaying the cell cycle exit, the loss of Hippo pathway protects cells from both developmental and stress induced apoptosis [19]–[22]. Although a mutation in de2f1 blocked inappropriate proliferation in Hippo pathway mutant cells, de2f1 wts double mutant cells, like wts single mutant cells, were fully resistant to a wave of apoptosis that normally occurs during pupal eye development (Figure 4A–B) or to DNA damage induced apoptosis in the larval eye disc following irradiation (Figure 4C). Thus, resistance to apoptosis, a hallmark of inactivation of Hippo pathway, remains unaffected by the loss of de2f1. This sustained resistance to apoptosis is a likely explanation for the slight increase of the number of interommatidial cells in de2f1 de2f2 wts mutant tissue and in dDP mutant cells overexpressing yki in comparison to wild type (Figure 2N). From these data we concluded that de2f1 is specifically required in Hippo pathway mutant cells to delay the cell cycle exit and sustain inappropriate proliferation posterior to the SMW.
The Loss of E2F–Mediated Control Does Not Block Induction of Yki Target Genes
A trivial explanation for the lack of inappropriate proliferation in de2f2 de2f1 wts is that inactivation of dE2F family members renders Yki inactive in these cells. To directly address this question we examined whether Yki is capable of inducing its target genes in dDP mutant cells. Drosophila inhibitor of apoptosis, dIAP1, has been recently shown to be a direct Yki transcriptional target [23],[24] and, together with Expanded [30], are commonly used to accurately assess the activity of the Hippo pathway. Notably, upregulation of Expanded and dIAP1 following yki overexpression was observed in wild type cells (Figure 5A, 5C) and to almost the same extent in clones of dDP mutant cells (Figure 5B, 5D). This suggests that the loss of E2F regulation does not prevent induction of at least two well established Yki targets.
Next, we investigated the expression of cyclin E since it is an E2F target [2] and is also considered to be a critical target of the Hippo pathway [19]–[22]. Clones of wts single and de2f1 wts double mutant cells were generated. As shown in Figure 6, the level of cyclin E was elevated in wts mutant cells and in de2f1 wts double mutant cells. Thus, the observation that induction of multiple Yki target genes is not compromised by the loss of E2F control implies that Yki remains active in dE2F deficient cells. Such a conclusion is in agreement with the resistance to apoptosis of de2f1 wts mutant cells, further evidence that Yki is fully functional in the absence of dE2F family.
Inactivation of the Hippo Pathway Leads to Elevation of E2F Activity
To further elucidate the role of de2f1 in Hippo pathway mutant cells, we used a PCNA-GFP reporter [31] to accurately measure E2F activity in clones of wts mutant cells. In a wild type eye disc, the PCNA-GFP reporter is expressed in a narrow stripe of cells prior to S phase entry in the SMW and is absent in the posterior region of the eye (Figure 7A). In contrast, wts mutant cells failed to downregulate the expression of the PCNA-GFP reporter posterior to the SMW (Figure 7B). This indicates that these cells have an abnormally high E2F activity. Importantly, the high E2F activity is due to de2f1 because the PCNA-GFP reporter is no longer expressed in de2f1 wts double mutant cells posterior to the SMW (Figure 7C). The finding that wts mutant cells have a high E2F activity posterior to the SMW is unexpected since the activator dE2F1, which provides the pattern of expression of the PCNA-GFP reporter in the eye disc [31], is normally downregulated in these cells (Figure 7D and [15]). Therefore, we examined the expression of dE2F1 in clones of wts and hpo mutant cells using a highly specific dE2F1 antibody (Figure 7E). In contrast to the wild type dE2F1 pattern, the expression of dE2F1 was highly abnormal in wts and hpo mutant cells (Figure 7F). First, the level of dE2F1 was elevated in cells that normally express dE2F1 within the MF. Second, dE2F1 was ectopically expressed in cells posterior to the MF. Thus, Hippo pathway mutant cells that inappropriately proliferate posterior to the SMW have an elevated E2F activity which is likely due to a high level of dE2F1.
To determine whether the high level of dE2F1 is a specific response to inactivation of the Hippo pathway or an indirect consequence of inappropriate cell proliferation posterior to the SMW, we examined the pattern of dE2F1 expression in clones of archipelago (ago) mutant cells. ago mutant cells, like wts or hpo mutant cells, fail to exit the cell cycle and proliferate posterior to the SMW [32]. In contrast to the abnormally high expression of dE2F1 in Hippo pathway mutant cells, the level of dE2F1 was not elevated in clones of ago mutant cells posterior to the SMW (Figure 7G). Furthermore, expression of cyclin E, which is sufficient to drive quiescent cells posterior to the SMW into the cell cycle [33],[34], did not result in an increase of the level of dE2F1 (Figure 7H). Finally, the level of another dE2F family member, dE2F2, is unaffected in wts mutant cells (Figure 7I). Thus, we concluded that dE2F1 is specifically upregulated following inactivation of the Hippo pathway.
As a further characterization, we tested whether de2f1 is transcriptionally induced in Hippo pathway mutant cells. The in vivo activity of the de2f1 promoter in hpo mutant cells was examined using an enhancer trap allele, de2f1729. The de2f1729 allele has been extensively used as an accurate measurement of de2f1 transcription [34]–[36]. This allele carries a lacZ gene inserted within the endogenous de2f1 gene. Therefore, the production of β-galactosidase reflects transcriptional activity at the de2f1 promoter. Clones of hpo mutant cells were induced in the eye disc and the expression of the lacZ gene from the de2f1729 allele was compared between the hpo mutant and adjacent wild type cells. Through detection of immunofluorescence, we found a higher level of β-Gal in hpo mutant cells than in wild type cells within the MF; thus, indicating that de2f1 transcription was induced (Figure 7J).
Finally, we depleted SL2 tissue culture cells of Hpo and Wts by RNA interference, (RNAi), and examined what effect this had on the level of dE2Fs by western blot analysis. Consistent with the effects seen in eye imaginal discs, the dE2F1 protein level was markedly increased in cells deficient of either Wts or Hpo, while the dE2F2 protein level remained constant (Figure 7K). To further biochemically characterize the properties of Hpo and Wts depleted cells we transiently transfected these depleted cells with an E2F reporter, PCNA-luc. Depletion of RBF1, the Drosophila pRB homolog, elevated the expression of the reporter by 2.5 fold in comparison to control treated cells (Figure 7L). Noticeably, the reporter was induced approximately 2 fold in Hpo and in Wts depleted cells, which is similar to the level seen in cells deficient of RBF1, the endogenous inhibitor of dE2F1. We concluded that inactivation of the Hippo pathway increases the level of dE2F1 and, more importantly, elevates E2F activity both in vivo and in vitro.
Discussion
Current models emphasize the importance of the E2F transcription factor in cell cycle control as one of the key downstream targets of the pRB tumor suppressor protein. Although E2F activity is rate limiting for S phase entry in tissue culture cells, ablation of the entire pool of Drosophila E2F is permissive for cell proliferation in vivo and only marginally affects animal development. However, it is unknown whether oncogene driven cell proliferation would also be insensitive to the loss of the entire dE2F family. This is an important conceptual point because unrestrained proliferation is a central property of a cancer cell, and this unrestrained proliferation is thought to be the result of deregulated E2F activity [5].
In this report, we addressed the role of the dE2F family members in cell proliferation following inactivation of the recently identified Hippo tumor suppressor pathway. In order to minimize any possible non-specific cell cycle effects seen in the presence of a de2f1 mutation, we have taken advantage of the previous observation that the complete ablation of E2F function in either de2f1 de2f2 double mutants or dDP single mutants is permissive for cell proliferation [15],[17],[18]. Our results strongly argue that the effect of the loss of E2F function on proliferation of Hippo pathway mutant cells is distinctly different in actively dividing cells and in cells undergoing unscheduled proliferation posterior to the SMW. In actively dividing cells that overexpress the pro-oncogene yki, a positive effector of the Hippo pathway, inactivation of the dE2F family has a minimal effect on cell proliferation; as Yki is capable of dramatically accelerating the rate of cell cycle progression of dDP mutant cells. Similarly, clones of cells which lack de2f1, de2f2, and wts (a negative regulator of Yki) appear to be relatively large; however, the quantification of a population doubling time in these mutant cells is technically inaccurate due to the requirement of two independent recombination events to generate triple mutant clones. Elimination of E2F function does not abolish Yki-dependent transcription, thus, we suggest that an elevated level of Yki target genes such as cyclin E and others may account for the accelerated proliferation of dDP mutant cells. Indeed, previous studies have shown that transient expression of cyclin E is sufficient to increase the rate of DNA synthesis of dDP mutant cells in the eye disc [15]. Thus, another conclusion that we drew from these results is that proliferation defects of dDP mutant cells are essentially rescued by Yki overexpression. This idea is consistent with the notion that Yki and the dE2Fs appear to share some common targets such as cyclin E. A caveat to this explanation is that for the exception of diap1, it is not known what putative targets are directly regulated by Yki. Secondly, since Yki fails to induce an E2F-reporter in the absence of de2f1, this suggests that Yki does not generally rescue E2F-dependent transcription in dDP mutant cells, but rather increases expression of a limited set of shared targets. Discerning how Yki overexpression accelerates the rate of proliferation in the absence of dE2F and how the interplay between Yki and dE2F occurs at common targets will be important directions in future studies.
In striking contrast to the results of inactivation of the entire dE2F family in actively dividing cells, we find that E2F function is required during Yki-driven unscheduled proliferation in otherwise quiescent cells posterior to the SMW in the eye imaginal disc. Overexpression of yki or inactivation of negative regulators of the Hippo tumor suppressor pathway, such as wts, renders cells of the eye imaginal disc refractory to the cell cycle exit signals and, as a result, cells continue to proliferate inappropriately [19],[21]. These abnormal cell cycles are fully blocked when E2F function is eliminated either by a mutation in the dDP gene or by combined ablation of both de2f1 and de2f2 genes. This conclusion is supported by the complete absence of cells in S phase or in mitosis posterior to the SMW in mutant clones. Furthermore, loss of E2F function in clones of wts mutant cells or in clones of cells that overexpress yki significantly reduces the number of supernumerary interommatidial cells that primarily arise due to inappropriate proliferation during larval and early pupal development. Interestingly, this reduction is very similar to that seen in clones of expanded mutant cells, an upstream negative regulator of Yki, albeit the molecular mechanism is distinctly different. Unlike de2f1 de2f2 wts triple mutants, expanded mutant cells proliferate inappropriately posterior to the SMW [37]. However, the supernumerary interommatidial cells are largely removed during the wave of developmental pupal apoptosis, while de2f1 de2f2 wts triple mutant cells are fully protected from cell death.
The results described here highlight the specific requirement for dE2F to maintain a proliferation potential in cells with high Yki activity posterior to the SMW. We emphasize that the loss of E2F control is permissive for cell proliferation in actively dividing wild type cells, as well as in actively dividing cells that overexpress yki. However, inactivation of the dE2F family fully prevents inappropriate divisions of Hippo pathway mutant cells that have failed to exit the cell cycle. While one could predict this result in the absence of de2f1 alone, since cell proliferation is severely reduced in de2f1 mutants, it was perhaps surprising to find that Yki-driven inappropriate proliferation posterior to the SMW is completely blocked by the total inactivation of the dE2F family. In this respect, these results are distinct from the predicted outcome of inactivation of other cell cycle regulators such as cyclin E or cyclin A on cell proliferation in Hippo pathway mutants. Mutations in these genes are likely to fully abrogate Yki induced proliferation in most, if not all, settings due to their fundamental roles in cell cycle regulation. In support of this distinction we note that the loss of the microRNA bantam has been shown to block Yki-driven proliferation in actively dividing cells of the wing disc, as well as cell proliferation during normal development [38],[39].
Why is Yki unable to drive cells into the cell cycle in the absence of E2F activity? One formal possibility is that Yki function is compromised in dE2F deficient cells posterior to the SMW. However, this seems unlikely since de2f1 wts double mutant cells, like wts single mutant cells, are fully protected from DNA damage induced apoptosis at larval stage and from developmental apoptosis in the pupal eye. Thus, inhibition of apoptosis, one of the key aspects of Yki function, remains unaltered. Consistently, Yki does induce its target genes, diap1 and Expanded, in dDP mutant cells. Hence, Yki activity does not appear to be generally affected by the loss of E2F function. We also note that Yki-dependent induction of cyclin E (this work) and cyclin B (our unpublished observations) still occurs in de2f1 deficient cells posterior to the SMW, yet these cells fail to proliferate posterior to the SMW. Thus, it remains a likely possibility that high cyclin E activity is capable of driving proliferation in actively dividing cells in the absence of dE2F, but not in cells during the cell cycle exit where cyclin E appears to require an assist from dE2F1 to sustain unscheduled cell proliferation. Although we cannot formally exclude the possibility that expression of some Yki target genes is deregulated in dE2F deficient cells, these results suggest that in the absence of dE2F, the Yki transcriptional program alone is insufficient to drive cell proliferation in otherwise quiescent cells posterior to the SMW. We emphasize that overexpression of dE2F1 is not sufficient to sustain proliferation in cells posterior to the SMW (for example see: [35],[40]) and that the phenotype of Hippo pathway mutant cells is likely to be a result of a cumulative effect of deregulation of a panel of Yki target genes. This is consistent with several studies that have shown that upon the cell cycle exit, cells become highly resistant to proliferative signals. For example, co-expression of dE2F1 and cyclin E is needed to bypass the cell cycle exit [40]. Similarly, combined ablation of two negative regulators of the cell cycle, RBF1 and the cdk2 inhibitor Dacapo, is required to prevent the exit from the cell cycle in the larval eye [41]. Thus, our results highlight the need for dE2F during inappropriate proliferation at the specific point when cells attempt to exit the cell cycle.
The Hippo pathway controls epithelial tissue growth by regulating the expression of genes that can promote cell proliferation and genes that can inhibit apoptosis. In humans, loss of expression of Lats1/2 (Wts homolog) [42] and mutations in WW45/Sav [43] and Mob (homolog of mats) [44] have been found in several tumor cell lines, while YAP expression is frequently elevated in cancers [45],[46]. Accordingly, mouse embryos lacking WW45/Sav display hyperplasia due to defects in cell cycle exit and terminal differentiation of epithelial progenitor cells [47]; while Lats1 −/− knockout animals develop soft-tissue sarcomas and ovarian stromal cell tumors [48]. Additionally, in a transgenic mouse model, YAP activation in the liver induces hyperplasia followed by tumor formation [46],[49]. Thus, the Hippo pathway represents a frequent mutational target and the outcome of its deregulation is tumorigenesis in both mice and humans. Although the status of the pRB pathway has not been determined in these tumors, it is generally thought that inactivation of the pRB pathway is an obligatory event in most, if not all, types of tumors [5]. In this respect, it is particularly intriguing that the ablation of Hippo function leads to an increase in dE2F1 level and elevation of E2F activity. Since the Hippo pathway is highly conserved between flies and mammals, it would be interesting to determine whether expression of mammalian E2fs is also induced following inactivation of the Hippo pathway. In support of this possibility we note that ectopic expression of YAP in transgenic mice increases the level of a well known E2F target gene, PCNA [49]. A comparison of de2f2 wts and de2f1 de2f2 wts mutant clones revealed that de2f1 is more important during inappropriate proliferation than de2f2. Importantly, the dE2F1 increase is not a coincidental result of an accelerated rate of proliferation in Hippo pathway mutant cells, since the level of dE2F1 is normal in clones of ago mutant cells, which, like wts mutants, proliferate posterior to the SMW. Although dE2F1 induction appears to be a result of a transcriptional response in hpo mutant cells and following overexpression of Yki (this work and [36]), whether the de2f1 promoter is directly regulated by Yki is currently not known. Further experiments will be necessary to decipher the exact mechanism by which Yki exerts its effect on de2f1 expression.
Finally, the data described here have a potential implication in cancer research. Inactivation of total E2F activity using a dominant negative form of E2F has been shown to impair re-entry into the cell cycle from quiescence in immortalized murine fibroblasts [9]. We find that a complete genetic ablation of the dE2F family fully blocks proliferation of Hippo pathway mutant cells posterior to the SMW. However, Hippo pathway mutant cells do not undergo a transient quiescence state during inappropriate proliferation since the mutant cells continuously express proliferation markers, such as phosH3, cyclin B, cyclin A, incorporate BrdU, and have a high level of an E2F reporter posterior to the SMW (this work and [27],[28],[43]). Thus, dE2F is required to sustain inappropriate cell proliferation specifically at the point when cells normally exit the cell cycle and enter quiescence. One implication of this result is that, at least, in the case of the inactivation of the Hippo pathway, the use of pharmacological E2F inhibitors might be beneficial in tumors in which cell cycle exit cues are induced even though these tumors do not necessarily respond to these signals and pass through temporary states of quiescence.
Materials and Methods
Fly Stocks and Mosaic Analysis
For mutant analysis, the following strong loss of function or null alleles were used:
de2f1729, de2f2c03344, wtsX1, hpoMGH4, ykiB5, ago1, and dDPa4.
Clones of homozygous mutant cells were generated with the ey-FLP/FRT technique. For clones of ago1 mutant cells the following genotype was used:
ey-FLP; ago1 FRT80B/P[Ubi-GFP] FRT80B
For clones of double mutant cells of de2f2 wts the following genotype was used:
ey-FLP; de2f2c03344FRT40A/P[Ubi-GFP] FRT40A; FRT82B wtsX1/FRT82B P[Ubi-GFP]
For clones of double mutant cells of wts de2f1 the following genotype was used:
ey-FLP; FRT82B de2f1729 wtsX1/ FRT82B P[Ubi-GFP]
Clones of triple mutant cells of de2f1 de2f2 wts were generated in:
ey-FLP; de2f2c03344FRT40A/P[Ubi-GFP] FRT40A; FRT82B de2f1729 wtsX1/FRT82B P[Ubi-GFP]
Activity at the de2f1 promoter in hpo mutant tissue was determined in larvae of the following genotype:
ey-FLP; FRT42D hpoMGH4/FRT42D P[Ubi-GFP]; FRT82B de2f1729/+
To determine the expression of the E2F reporter, PCNA-GFP, in wts mutant and in de2f1 wts double mutant cells the following genotypes were used:
ey-FLP; PCNA-GFP/+; FRT82B wtsX1/FRT82B P[arm-LacZ]
ey-FLP; PCNA-GFP/+; FRT82B de2f1729 wtsX1/FRT82B P[arm-LacZ]
Analysis of yki overexpression was done with the MARCM system [25] in larvae of the following genotypes:
y w hs-FLP70 tub-GAL4 UAS-GFP-6XMyc.NLS; FRT42D tub-GAL80/FRT42D dDPa4; UAS-Yki/+
y w hs-FLP70 tub-GAL4 UAS-GFP-6XMyc.NLS; FRT42D tub-GAL80/FRT42D; UAS-Yki/+
y w hs-FLP70 tub-GAL4 UAS-GFP-6XMyc.NLS; FRT42D tub-GAL80/FRT42D
eyFLP UAS-GFP; tub-GAL4 FRT82B P[UAS-yki]/FRT82B tub-GAL80
Analysis of cyclin E overexpression was done with the MARCM system [25] in:
y w hs-FLP70 tub-GAL4 UAS-GFP-6XMyc.NLS; FRT42D tub-GAL80/FRT42D; UAS-cyclinE/+
To determine the cell population doubling time, clones of dDP mutant cells were induced 48 hrs AED and discs were dissected and fixed 66–70 hrs later. A standard error of the mean was calculated for each genotype. To determine number of interommatidial cells for the pupal retinae, bristle, secondary, and tertiary cells for one ommatidium were counted. One ommatidium was defined as a single cluster of 4 cone cells, 2 primary cells, 3 bristle cells, 3 tertiary cells, and 6 secondary cells. A standard deviation of the mean was taken to determine significance. To measure the area per clone the histogram function in Adobe Photoshop was used and a standard error of the mean was taken to determine significance.
Immunohistochemistry
Antibodies used were as follows: mouse anti-cyclinE 1∶20 (from B. Edgar), guinea pig anti-Expanded 1∶500 (from R. Fehon), mouse anti-Discs Large 1∶400 (DSHB), mouse anti-BrdU 1∶50 (Beckton Dickinson ), rabbit anti-dE2F1 1∶400 (from C. Seum), mouse anti-β-galactosidase 1∶30 (DSHB), rabbit anti-GFP 1∶200 (Invitrogen), rabbit anti-C3 (Cleaved Caspase3) 1∶100 (Cell Signaling), rabbit anti-dE2F2 1∶100, rabbit anti-phosH3 1∶175 (Upstate), and Cy3, Cy5 (Jackson Immunolaboratories) and Alexa488 (Invitrogen) conjugated anti-mouse and anti-rabbit secondary antibodies. Larval and pupal tissues were fixed in 4% formaldehyde for 30 minutes on ice, washed in phosphate-buffered saline, and then incubated with antibodies overnight at 4°C in phosphate-buffered saline, 10% normal goat serum, and 0.3% Triton-X100 as previously described [29]. To detect dE2F1 protein, fixation was adjusted to 40 minutes on ice and then treated as described above. To detect cyclin E protein in larval eye imaginal disc, PLP fixation was used and then the same protocol described above was used. To detect S phases, dissected larval or pupal eye discs were labeled with BrdU for 2 hrs at room temperature and then the eye discs were fixed overnight in 1.5% formaldehyde at 4°C. Apoptosis was measured in pupal eye discs 30 hrs APF. To measure apoptosis following DNA damage, larvae were exposed to 40 Grays of irradiation and then imaginal discs were dissected 4 hrs later.
S2 Cell Manipulations
RNAi and transient transfections were done as described previously[29]. For western blot analysis, S2 cells were lysed in NP40 buffer, frozen at −80°C for 1 hr, thawed, spun down, and then boiled in protein sample buffer. Samples were resolved using SDS-PAGE on 7% gels, transferred to Immobilon-P membrane (Millipore), and incubated with the following antibodies: mouse anti-E7(tubulin) 1∶9000 (DSHB), guinea pig anti-Wts 1∶10,000 (From K. Irvine), rabbit anti-dE2F2 1∶2,000, guinea pig anti-dE2F1 1∶7,000 (from T. Orr-Weaver).
Acknowledgments
We are grateful to B. Edgar, R. Fehon, I. Hariharan, K. Harvey, K. Irvine, L. Johnston, A. Katzen, Z. Lai, K. Moberg, T. Orr-Weaver, G. Struhl, N. Tapon, J. Treisman, the Developmental Studies Hybridoma Bank (University of Iowa) and the Bloomington Stock Center for fly stocks and antibodies. We thank V. Rasheva and A. Ambrus for technical assistance. We thank N. Dyson, A. Katzen, G. Ramsey and M. Truscott for critical discussions.
Footnotes
The authors have declared that no competing interests exist.
This work was supported by grant GM079774 from NIH to MVF.
References
- 1.DeGregori J, Johnson DG. Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis. Curr Mol Med. 2006;6:739–748. doi: 10.2174/1566524010606070739. [DOI] [PubMed] [Google Scholar]
- 2.Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaintances with new faces. Oncogene. 2005;24:2810–2826. doi: 10.1038/sj.onc.1208612. [DOI] [PubMed] [Google Scholar]
- 3.Blais A, Dynlacht BD. Hitting their targets: an emerging picture of E2F and cell cycle control. Curr Opin Genet Dev. 2004;14:527–532. doi: 10.1016/j.gde.2004.07.003. [DOI] [PubMed] [Google Scholar]
- 4.Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol. 2002;3:11–20. doi: 10.1038/nrm714. [DOI] [PubMed] [Google Scholar]
- 5.Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70. doi: 10.1016/s0092-8674(00)81683-9. [DOI] [PubMed] [Google Scholar]
- 6.Ziebold U, Lee EY, Bronson RT, Lees JA. E2F3 loss has opposing effects on different pRB-deficient tumors, resulting in suppression of pituitary tumors but metastasis of medullary thyroid carcinomas. Mol Cell Biol. 2003;23:6542–6552. doi: 10.1128/MCB.23.18.6542-6552.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Yamasaki L, Bronson R, Williams BO, Dyson NJ, Harlow E, et al. Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/−)mice. Nat Genet. 1998;18:360–364. doi: 10.1038/ng0498-360. [DOI] [PubMed] [Google Scholar]
- 8.Lee EY, Cam H, Ziebold U, Rayman JB, Lees JA, et al. E2F4 loss suppresses tumorigenesis in Rb mutant mice. Cancer Cell. 2002;2:463–472. doi: 10.1016/s1535-6108(02)00207-6. [DOI] [PubMed] [Google Scholar]
- 9.Rowland BD, Denissov SG, Douma S, Stunnenberg HG, Bernards R, et al. E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. Cancer Cell. 2002;2:55–65. doi: 10.1016/s1535-6108(02)00085-5. [DOI] [PubMed] [Google Scholar]
- 10.Wu C-L, Classon M, Dyson N, Harlow E. Expression of dominant-negative mutant DP-1 blocks cell cycle progression in G1. Mol Cell Biol. 1996;16:3698–3706. doi: 10.1128/mcb.16.7.3698. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Maehara K, Yamakoshi K, Ohtani N, Kubo Y, Takahashi A, et al. Reduction of total E2F/DP activity induces senescence-like cell cycle arrest in cancer cells lacking functional pRB and p53. J Cell Biol. 2005;168:553–560. doi: 10.1083/jcb.200411093. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Wu L, Timmers C, Maiti B, Saavedra HI, Sang L, et al. The E2F1-3 transcription factors are essential for cellular proliferation. Nature. 2001;414:457–462. doi: 10.1038/35106593. [DOI] [PubMed] [Google Scholar]
- 13.Gaubatz S, Lindeman GJ, Jakoi L, Nevins JR, Livingston DM, et al. E2F4 and E2F5 play an essential role in pocket protein-mediated G1 control. Mol Cell. 2000;6:729–735. doi: 10.1016/s1097-2765(00)00071-x. [DOI] [PubMed] [Google Scholar]
- 14.Li J, Ran C, Li E, Gordon F, Comstock G, et al. Synergistic function of E2F7 and E2F8 is essential for cell survival and embryonic development. Dev Cell. 2008;14:62–75. doi: 10.1016/j.devcel.2007.10.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Frolov MV, Moon NS, Dyson NJ. dDP is needed for normal cell proliferation. Mol Cell Biol. 2005;25:3027–3039. doi: 10.1128/MCB.25.8.3027-3039.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Duronio RJ, O'Farrell PH, Xie J-E, Brook A, Dyson N. The transcription factor E2F is required for S phase during Drosophila embryogenesis. Genes Dev. 1995;9:1445–1455. doi: 10.1101/gad.9.12.1445. [DOI] [PubMed] [Google Scholar]
- 17.Royzman I, Whittaker AJ, Orr-Weaver TL. Mutations in Drosophila DP and E2F distinguish G1-S progression from an associated transcriptional program. Genes Dev. 1997;11:1999–2011. doi: 10.1101/gad.11.15.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Frolov MV, Huen DS, Stevaux O, Dimova D, Balczarek-Strang K, et al. Functional antagonism between E2F family members. Genes Dev. 2001;15:2146–2160. doi: 10.1101/gad.903901. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Pan D. Hippo signaling in organ size control. Genes Dev. 2007;21:886–897. doi: 10.1101/gad.1536007. [DOI] [PubMed] [Google Scholar]
- 20.Saucedo LJ, Edgar BA. Filling out the Hippo pathway. Nat Rev Mol Cell Biol. 2007;8:613–621. doi: 10.1038/nrm2221. [DOI] [PubMed] [Google Scholar]
- 21.Harvey K, Tapon N. The Salvador-Warts-Hippo pathway-an emerging tumour-suppressor network. Nat Rev Cancer. 2007;7:182–191. doi: 10.1038/nrc2070. [DOI] [PubMed] [Google Scholar]
- 22.Hariharan IK. Growth regulation: a beginning for the hippo pathway. Curr Biol. 2006;16:R1037–1039. doi: 10.1016/j.cub.2006.11.012. [DOI] [PubMed] [Google Scholar]
- 23.Zhang L, Ren F, Zhang Q, Chen Y, Wang B, et al. The TEAD/TEF family of transcription factor Scalloped mediates Hippo signaling in organ size control. Dev Cell. 2008;14:377–387. doi: 10.1016/j.devcel.2008.01.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Wu S, Liu Y, Zheng Y, Dong J, Pan D. The TEAD/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. Dev Cell. 2008;14:388–398. doi: 10.1016/j.devcel.2008.01.007. [DOI] [PubMed] [Google Scholar]
- 25.Lee T, Luo L. Mosaic analysis with a repressible cell marker (MARCM) for Drosophila neural development. Trends Neurosci. 2001;24:251–254. doi: 10.1016/s0166-2236(00)01791-4. [DOI] [PubMed] [Google Scholar]
- 26.Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell. 2005;122:421–434. doi: 10.1016/j.cell.2005.06.007. [DOI] [PubMed] [Google Scholar]
- 27.Wu S, Huang J, Dong J, Pan D. hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell. 2003;114:445–456. doi: 10.1016/s0092-8674(03)00549-x. [DOI] [PubMed] [Google Scholar]
- 28.Harvey KF, Pfleger CM, Hariharan IK. The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell. 2003;114:457–467. doi: 10.1016/s0092-8674(03)00557-9. [DOI] [PubMed] [Google Scholar]
- 29.Ambrus AM, Nicolay BN, Rasheva VI, Suckling RJ, Frolov MV. dE2F2-independent rescue of proliferation in cells lacking an activator dE2F1. Mol Cell Biol. 2007;27:8561–8570. doi: 10.1128/MCB.01068-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Hamaratoglu F, Willecke M, Kango-Singh M, Nolo R, Hyun E, et al. The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol. 2006;8:27–36. doi: 10.1038/ncb1339. [DOI] [PubMed] [Google Scholar]
- 31.Thacker SA, Bonnette PS, Duronio RJ. The contribution of E2F-regulated transcription to Drosophila PCNA gene function. Curr Biol. 2003;13:53–58. doi: 10.1016/s0960-9822(02)01400-8. [DOI] [PubMed] [Google Scholar]
- 32.Moberg KH, Bell DW, Wahrer DC, Haber DA, Hariharan IK. Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature. 2001;413:311–316. doi: 10.1038/35095068. [DOI] [PubMed] [Google Scholar]
- 33.Buttitta LA, Edgar BA. Mechanisms controlling cell cycle exit upon terminal differentiation. Curr Opin Cell Biol. 2007;19:697–704. doi: 10.1016/j.ceb.2007.10.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Reis T, Edgar BA. Negative regulation of dE2F1 by cyclin-dependent kinases controls cell cycle timing. Cell. 2004;117:253–264. doi: 10.1016/s0092-8674(04)00247-8. [DOI] [PubMed] [Google Scholar]
- 35.Brook A, Xie J-E, Du W, Dyson N. Requirements for dE2F function in proliferating cells and in post-mitotic differentiating cells. EMBO J. 1996;15:3676–3683. [PMC free article] [PubMed] [Google Scholar]
- 36.Goulev Y, Fauny JD, Gonzalez-Marti B, Flagiello D, Silber J, et al. SCALLOPED interacts with YORKIE, the nuclear effector of the hippo tumor-suppressor pathway in Drosophila. Curr Biol. 2008;18:435–441. doi: 10.1016/j.cub.2008.02.034. [DOI] [PubMed] [Google Scholar]
- 37.Pellock BJ, Buff E, White K, Hariharan IK. The Drosophila tumor suppressors Expanded and Merlin differentially regulate cell cycle exit, apoptosis, and Wingless signaling. Dev Biol. 2007;304:102–115. doi: 10.1016/j.ydbio.2006.12.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Thompson BJ, Cohen SM. The Hippo pathway regulates the bantam microRNA to control cell proliferation and apoptosis in Drosophila. Cell. 2006;126:767–774. doi: 10.1016/j.cell.2006.07.013. [DOI] [PubMed] [Google Scholar]
- 39.Nolo R, Morrison CM, Tao C, Zhang X, Halder G. The bantam microRNA is a target of the hippo tumor-suppressor pathway. Curr Biol. 2006;16:1895–1904. doi: 10.1016/j.cub.2006.08.057. [DOI] [PubMed] [Google Scholar]
- 40.Buttitta LA, Katzaroff AJ, Perez CL, de la Cruz A, Edgar BA. A double-assurance mechanism controls cell cycle exit upon terminal differentiation in Drosophila. Dev Cell. 2007;12:631–643. doi: 10.1016/j.devcel.2007.02.020. [DOI] [PubMed] [Google Scholar]
- 41.Firth LC, Baker NE. Extracellular signals responsible for spatially regulated proliferation in the differentiating Drosophila eye. Dev Cell. 2005;8:541–551. doi: 10.1016/j.devcel.2005.01.017. [DOI] [PubMed] [Google Scholar]
- 42.Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, et al. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res. 2005;11:1380–1385. doi: 10.1158/1078-0432.CCR-04-1773. [DOI] [PubMed] [Google Scholar]
- 43.Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, et al. salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell. 2002;110:467–478. doi: 10.1016/s0092-8674(02)00824-3. [DOI] [PubMed] [Google Scholar]
- 44.Lai ZC, Wei X, Shimizu T, Ramos E, Rohrbaugh M, et al. Control of cell proliferation and apoptosis by mob as tumor suppressor, mats. Cell. 2005;120:675–685. doi: 10.1016/j.cell.2004.12.036. [DOI] [PubMed] [Google Scholar]
- 45.Zhao B, Wei X, Li W, Udan RS, Yang Q, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21:2747–2761. doi: 10.1101/gad.1602907. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Dong J, Feldmann G, Huang J, Wu S, Zhang N, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007;130:1120–1133. doi: 10.1016/j.cell.2007.07.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Lee JH, Kim TS, Yang TH, Koo BK, Oh SP, et al. A crucial role of WW45 in developing epithelial tissues in the mouse. Embo J. 2008;27:1231–1242. doi: 10.1038/emboj.2008.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.St John MA, Tao W, Fei X, Fukumoto R, Carcangiu ML, et al. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat Genet. 1999;21:182–186. doi: 10.1038/5965. [DOI] [PubMed] [Google Scholar]
- 49.Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, et al. YAP1 Increases Organ Size and Expands Undifferentiated Progenitor Cells. Curr Biol. 2007;17:2054–2060. doi: 10.1016/j.cub.2007.10.039. [DOI] [PubMed] [Google Scholar]